xylo+dex

Phase 3Small molecule

MMcNeil AB

xylo+dex is one of 28 small molecule programs targeting Nasal congestion. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Nasal CongestionActive, not recruiting

Nasal CongestionPhase 3

Active, not recruiting

Competition

Competitive Landscape

33 competitors in Nasal Congestion

#DrugCompanyPhaseTrials

Acanya

Keflex

Benadryl

1 4

Sudafed

KKenvue Brands

Approved

1 5

Kenalog

BBausch Health Americas, Inc.

Approved

—6

Cortef

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Kenalog

Alvesco

AAzurity Pharmaceuticals

Approved

—9

Decadron

AAspen Global Incorporated

Approved

—10

Ephedrine Sulfate

DDr. Reddys Laboratories, SA

Approved

—

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Nasal congestion1 trial

A Study to Compare Two Formulations of Xylometazoline/Dexpanthenol Nasal Spray for the Treatment of Nasal Congestion.

Completed·MMcNeil AB·Phase 3·NCT03439436·140 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for xylo+dex. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — xylo+dex compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for xylo+dex. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — McNeil AB company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: MMcNeil AB

xylo+dex

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Nasal congestion1 trial

References

Drug Info

Quick Facts

Related News